arrow_back Back Filing freshness 10-Q Q2 FY2025 SEC EDGAR

Traws Pharma, Inc.

TRAW
$0.49 ▼ -0.01 (-1.96%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
59 Visible periods
26 Metrics
Absolute Benchmarks
Price Chart
18
Health
Poor
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, Traws Pharma, Inc. shows weak fundamentals, weighed down by FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $7.8M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC None
FCF / Share $-0.47
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

59-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-3.05M
↓ -233.8%
Operating Margin Operating profit as % of sales
-45.7%
↑ +74.6%
FCF / Share Free cash flow per share
$-0.47
↓ -95.4%

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • FCF / Net IncomeFCF / Net Income of -1.98x is weak on an absolute basis (target > 1x)

Health Breakdown

Cash Quality
18

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 16 years · 59 quarters